Modera Wealth Management LLC Sells 269 Shares of Hologic, Inc. (NASDAQ:HOLX)

Modera Wealth Management LLC lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,065 shares of the medical equipment provider’s stock after selling 269 shares during the period. Modera Wealth Management LLC’s holdings in Hologic were worth $1,446,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HOLX. General Partner Inc. purchased a new position in shares of Hologic during the 4th quarter valued at about $26,000. Venturi Wealth Management LLC grew its position in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares during the last quarter. First Horizon Advisors Inc. raised its stake in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 159 shares during the last quarter. Finally, Covestor Ltd boosted its stake in shares of Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 133 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Trading Down 0.2 %

NASDAQ:HOLX opened at $63.27 on Tuesday. The company has a 50-day moving average price of $68.98 and a 200-day moving average price of $75.78. The stock has a market cap of $14.20 billion, a price-to-earnings ratio of 19.96, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $62.69 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on HOLX shares. Mizuho decreased their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Royal Bank of Canada decreased their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Morgan Stanley dropped their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. BNP Paribas raised Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Hologic presently has a consensus rating of “Hold” and a consensus target price of $85.77.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.88% of the stock is currently owned by corporate insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.